Vincent Mascitti

USPTO Granted Patents = 11 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 12)

Average Co-Inventor Count = 1.7

ph-index = 6

Forward Citations = 70(Granted Patents)

Company Filing History:

University of California

patents

where one patent can have more than one assignee

Years Active: 2011-2020

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10851367 - Tissue-specific genome engineering using CRISPR-Cas9 (2020-12-01),

2. 10813942 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2020-10-27),

3. 10376531 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2019-08-13),

4. 10039778 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2018-08-07),

5. 9617293 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2017-04-11),

6. 9439902 - Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives (2016-09-13),

7. 9439901 - Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives (2016-09-13),

8. 9340553 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2016-05-17),

9. 9308204 - Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives (2016-04-12),

10. 8669380 - Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives (2014-03-11),

11. 8080580 - Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives (2011-12-20),

Title: Vincent Mascitti: Pioneering Innovator in Genome Engineering

Introduction: Vincent Mascitti, a renowned inventor based in Groton, CT, has made significant contributions in the field of genome engineering. With a total of 11 patents to his name, Mascitti's innovative work has paved the way for groundbreaking advancements in the treatment of various diseases and disorders.

Latest Patents:

1. "Tissue-specific genome engineering using CRISPR-Cas9": Mascitti's recent patent focuses on compounds and compositions for treating diseases, conditions, and disorders using CRISPR-Cas9 technology.

2. "Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR": This patent describes the uses of specific compounds as targeting agents for the treatment of diseases mediated by asialoglycoprotein receptor (ASGPR).

Career Highlights: Mascitti has held pivotal roles at prominent institutions such as Pfizer Corporation and the University of California. His work at these esteemed organizations has demonstrated his expertise and commitment to pushing the boundaries of scientific innovation.

Collaborations: Throughout his career, Mascitti has collaborated with esteemed professionals in the field, including Spiros Liras and Benjamin A Thuma. These collaborations have led to the development of cutting-edge technologies and solutions in genome engineering.

Conclusion: Vincent Mascitti's ingenuity and dedication in the field of genome engineering have significantly impacted the healthcare industry. His patents and collaborative efforts reflect a commitment to advancing scientific research for the betterment of society. Mascitti's contributions continue to inspire future innovators and researchers in the quest for groundbreaking medical advancements.

This text is generated by artificial intelligence and may not be accurate.